Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved US-based B. Braun Medical's Nutrilipid 20% (IV fat emulsion) for parenteral nutrition therapy in adult and pediatric patients.
Subscribe to our email newsletter
Nutrilipid 20% is indicated as a source of calories and essential fatty acids for parenteral nutrition and also as a source of essential fatty acids when a deficiency occurs when oral or enteral nutrition is not possible, insufficient, or contraindicated.
The FDA approval will help alleviate the short supply of lipid emulsion products the US has seen over the past two years.
B.Braun vice president of Pharmaceutical Marketing Rick Williamson said the company is happy that the FDA has granted approval for Nutrilipid 20%.
"Through our state-of-the-art production facility, we are committed to providing quality clinical nutrition products so that patients have access to parenteral nutrition they often critically need," Williamson said.
"B.Braun continues to expand upon its customized approach to clinical nutrition and compounding to meet the needs of patients along the entire clinical pathway."